On August 27, 2015 OncoMed reported New biomarker data related to OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) Phase 1b/2 PINNACLE clinical trial of tarextumab (Anti-Notch 2/3, OMP-59R5) in small cell lung cancer (SCLC) will be presented by academic collaborator, Anne Chiang M.D., Ph.D., of the Yale School of Medicine, during a mini oral discussion session at the upcoming 16th World Conference on Lung Cancer taking place September 6-9 in Denver, CO (Press release, OncoMed, AUG 27, 2015, View Source [SID:1234507353]). Details for the presentation are provided below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wednesday, September 9, 2015

Mini27.08: NOTCH3 Protein Expression and Outcome in Small Cell Lung Cancer (SCLC) and Therapeutic Targeting with Tarextumab (Anti-Notch 2/3)

Lead author: Anne Chiang, M.D., Ph.D., Yale School of Medicine

Session: Mini Oral 27: Biology and Other Issues in SCLC

Location: Colorado Convention Center, Room 605+607

ID: 2999